Catalent (NYSE:CTLT) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Catalent (NYSE:CTLT) in a report released on Saturday morning. The brokerage issued a sell rating on the stock.

Separately, Stephens restated an equal weight rating and set a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Catalent has a consensus rating of Hold and a consensus target price of $54.05.

Catalent Price Performance

Catalent stock opened at $56.47 on Friday. Catalent has a 12 month low of $31.80 and a 12 month high of $60.20. The company has a current ratio of 2.51, a quick ratio of 1.77 and a debt-to-equity ratio of 1.37. The business’s 50 day simple moving average is $55.52 and its 200 day simple moving average is $53.44. The company has a market cap of $10.22 billion, a price-to-earnings ratio of -9.26, a PEG ratio of 6.59 and a beta of 1.20.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.21 by ($0.36). Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. The firm had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.11 billion. Sell-side analysts forecast that Catalent will post 0.28 EPS for the current year.

Insiders Place Their Bets

In other Catalent news, insider Ricky Hopson sold 1,401 shares of the stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total value of $76,018.26. Following the completion of the sale, the insider now owns 20,617 shares in the company, valued at approximately $1,118,678.42. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CTLT. Vanguard Group Inc. grew its holdings in shares of Catalent by 1.8% in the third quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock worth $931,909,000 after acquiring an additional 365,648 shares during the period. Capital World Investors lifted its position in Catalent by 6.1% during the fourth quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock valued at $857,264,000 after purchasing an additional 1,098,474 shares in the last quarter. Nomura Holdings Inc. lifted its position in Catalent by 149.4% during the fourth quarter. Nomura Holdings Inc. now owns 11,487,342 shares of the company’s stock valued at $516,126,000 after purchasing an additional 6,881,914 shares in the last quarter. Cadian Capital Management LP lifted its position in Catalent by 14.3% during the fourth quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock valued at $272,473,000 after purchasing an additional 759,600 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its position in Catalent by 65.9% during the third quarter. Ameriprise Financial Inc. now owns 3,483,494 shares of the company’s stock valued at $158,601,000 after purchasing an additional 1,384,313 shares in the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.